Healthcare Industry News: oral cancer
News Release - August 7, 2018
Vigilant Biosciences Names William Brodie as Chief Executive OfficerFORT LAUDERDALE, Fla., Aug. 7, 2018 -- (Healthcare Sales & Marketing Network) -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of oral and throat cancer, today announced the appointment of William "Bill" Brodie as Chief Executive Officer.
Bill brings over 20 years of experience in sales and management roles. Previously, he served as Chief Commercial Officer of Vital Connect, a leader in wearable biosensor technology for wireless hospital and remote patient monitoring. He earlier served as Global Vice President of Sales and Marketing at myoscience where he built and led all commercial operations. Bill also served as Vice President of Global Sales at Solta Medical. From 1998 to 2006, Bill served as Vice President of Sales and Field Operations and held various sales management positions with Benco Dental, a $400M company specializing in dental office equipment sales, office design and supply management. His expertise includes team leadership, sales management and international business management.
"We are thrilled to welcome Bill to our leadership team," said Tim Barabe, a member of the Vigilant Biosciences Board of Directors. "His extensive commercialization experience will bring tremendous value to Vigilant Biosciences as we continue to advance our oral cancer product line, as well as other products in our pipeline."
Bill earned a Master of Science in Management from Georgia Institute of Technology and a Bachelor of Science in Mathematics from Rollins College.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of oral and throat cancer. Vigilant's OncAlert™ oral cancer product line includes point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The OncAlert oral cancer RAPID Test and the OncAlert oral cancer LAB Test are CE Marked. The OncAlert oral cancer product line is not yet available for sale in the U.S. For more information, visit www.vigilantbiosciences.com.
Source: Vigilant Biosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.